Investors & Media Press Releases

Press Releases

Summary Toggle

07.31.2020

Summary Toggle Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD

Summary ToggleNEW YORK and BASEL, Switzerland , July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, announced today that its subsidiary has signed a three-year Clinical Supply Agreement (“CSA”) with
Read More

PDF Version
Read More
Summary Toggle

06.10.2020

Summary Toggle Axovant Announces Year-End Financial Results and Expected Key Clinical Milestones in Q4 2020

Summary ToggleCompleted enrollment of cohort 2 of SUNRISE-PD Phase 2 study of AXO-Lenti-PD in Parkinson’s disease, with data from this cohort expected in Q4 2020 Completed enrollment of low-dose cohort of Phase 1/2 clinical study of AXO-AAV-GM1 for GM1 gangliosidosis, with data from this cohort expected in Q4
Read More

PDF Version
Read More
Summary Toggle

06.08.2020

Summary Toggle Axovant Completes Enrollment of Low-Dose Cohort in Phase 1/2 Study of AXO-AAV-GM1 and Expands Study to Include Type I (Infantile Onset) Patients with GM1 Gangliosidosis

Summary Toggle- Six-month data from low-dose cohort expected in Q4 2020 - IND amended to include Type I (infantile onset) patients and to evaluate a higher dose - Expect to initiate high-dose cohort in 2H 2020 NEW YORK and BASEL, Switzerland , June 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd.
Read More

PDF Version
Read More
Summary Toggle

05.28.2020

Summary Toggle Axovant Gene Therapies to Present at the 2020 Jefferies Global Virtual Healthcare Conference

Summary ToggleNEW YORK and BASEL, Switzerland , May 28, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that Parag Meswani , Pharm.D., SVP of Commercial Strategy and Operations, will
Read More

PDF Version
Read More
Summary Toggle

05.07.2020

Summary Toggle Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

Summary ToggleNEW YORK and BASEL, Switzerland , May 07, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced upcoming presentations regarding its investigational gene therapy programs,
Read More

PDF Version
Read More
Summary Toggle

04.24.2020

Summary Toggle Axovant Announces Full Prepayment of Outstanding Loan from Hercules Capital

Summary ToggleCompany’s balance sheet is now free of debt NEW YORK and BASEL, Switzerland , April 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it had prepaid in full its $15.7 million
Read More

PDF Version
Read More
Summary Toggle

04.15.2020

Summary Toggle Axovant Announces Partnership with Invitae to Increase Access to Genetic Testing and Accelerate Diagnoses of GM1 and GM2 Gangliosidosis

Summary TogglePartnership to reduce barriers to genetic diagnosis through sponsored testing for lysosomal storage diseases Initiative supports identification of patients with GM1 and GM2 gangliosidosis who are currently misdiagnosed or undiagnosed NEW YORK and BASEL, Switzerland , April 15, 2020 (GLOBE NEWSWIRE)
Read More

PDF Version
Read More
Summary Toggle

04.08.2020

Summary Toggle Axovant Provides Business and Operations Update During the COVID-19 Pandemic

Summary ToggleCompleted dosing of all patients in second cohort of AXO-Lenti-PD dose escalation study At present, Company remains on track to achieve key 2020 milestones NEW YORK and BASEL, Switzerland , April 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd.
Read More

PDF Version
Read More
Summary Toggle

03.31.2020

Summary Toggle Axovant to Participate in Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

Summary ToggleNEW YORK and BASEL, Switzerland , March 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that management will participate in the virtual Guggenheim Healthcare Talks:
Read More

PDF Version
Read More
Summary Toggle

02.24.2020

Summary Toggle Axovant Gene Therapies Announces Closing of $74.7 Million Public Offering of Common Shares and Prefunded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Summary ToggleNEW YORK and BASEL, Switzerland , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten public offering of 16,631,336 common shares, including the full exercise of the underwriters’ option to
Read More

PDF Version
Read More

Investors & Media Press Releases

Press Releases

Email Alerts

Print

Email

Search

Investors & Media Press Releases

Press Releases

Toolbar

Email Alerts

Print

Email

Search